CD4+ T Cell Immune Specificity Changes After Vaccination in Healthy And COVID-19 Convalescent Subjects.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 09 08 2021
accepted: 29 12 2021
entrez: 7 2 2022
pubmed: 8 2 2022
medline: 22 2 2022
Statut: epublish

Résumé

The immune response promoted by SARS-CoV-2 vaccination is relevant to develop novel vaccines and optimized prevention strategies. We analyzed the adaptive immunity in healthy donors (HD) and convalescent individuals (CD), before and after administering BNT162b2 vaccine. Our results revealed specific changes in CD4+ T cell reactivity profile in vaccinated HD and CD, with an increase in S1 and S2 positive individuals, proportionally higher for S2. On the contrary, NCAP reactivity observed in HD and CD patients was no longer detectable after vaccination. Despite the substantial antibody response in CD, MPro-derived peptides did not elicit CD4+ lymphocyte activation in our assay in either condition. HD presented an increment in anti-S and anti-RBD IgG after first dose vaccination, which increased after the second vaccination. Conversely, anti-S and anti-RBD IgG and IgA titers increased in already positive CD after first dose administration, remaining stable after second dose inoculation. Interestingly, we found a strong significant correlation between S1-induced CD4+ response and anti-S IgA pre-vaccination, which was lost after vaccine administration.

Identifiants

pubmed: 35126347
doi: 10.3389/fimmu.2021.755891
pmc: PMC8807633
doi:

Substances chimiques

Immunoglobulin A 0
Immunoglobulin G 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

755891

Informations de copyright

Copyright © 2022 Esparcia-Pinedo, Martínez-Fleta, Ropero, Vera-Tomé, Reyburn, Casasnovas, Rodríguez Frade, Valés-Gómez, Vilches, Martín-Gayo, Muñoz-Calleja, Sanchez-Madrid and Alfranca.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Science. 2021 Dec 3;374(6572):abm0829
pubmed: 34648302
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33939647
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33956667
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Nat Commun. 2021 Apr 6;12(1):2055
pubmed: 33824342
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nat Commun. 2021 Feb 19;12(1):1152
pubmed: 33608538
Immunity. 2021 Feb 9;54(2):340-354.e6
pubmed: 33567252
J Clin Invest. 2021 May 17;131(10):
pubmed: 33830946
J Immunol. 2021 Sep 1;207(5):1344-1356
pubmed: 34389625
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
J Immunol. 2020 Dec 1;205(11):3130-3140
pubmed: 33148714
Immunity. 2020 Dec 15;53(6):1258-1271.e5
pubmed: 33296686
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Nat Rev Immunol. 2021 Aug;21(8):475-484
pubmed: 34211186
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
J Clin Invest. 2020 Dec 1;130(12):6631-6638
pubmed: 32966269
N Engl J Med. 2021 May 20;384(20):1959-1961
pubmed: 33755375

Auteurs

Laura Esparcia-Pinedo (L)

Immunology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.

Pedro Martínez-Fleta (P)

Immunology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.

Noelia Ropero (N)

Immunology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.

Paula Vera-Tomé (P)

Immunology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.

Hugh T Reyburn (HT)

Department of Immunology and Oncology, Centro Nacional de Biotecnologia/Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

José M Casasnovas (JM)

Department of Macromolecular Structures, Centro Nacional de Biotecnologia/Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

José M Rodríguez Frade (JM)

Department of Immunology and Oncology, Centro Nacional de Biotecnologia/Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

Mar Valés-Gómez (M)

Department of Immunology and Oncology, Centro Nacional de Biotecnologia/Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

Carlos Vilches (C)

Immunogenetics and Histocompatibility, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.

Enrique Martín-Gayo (E)

Immunology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.
Department of Medicine, School of Medicine, Universidad Autónoma of Madrid, Madrid, Spain.

Cecilia Muñoz-Calleja (C)

Immunology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.
Department of Medicine, School of Medicine, Universidad Autónoma of Madrid, Madrid, Spain.

Francisco Sanchez-Madrid (F)

Immunology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.
Department of Medicine, School of Medicine, Universidad Autónoma of Madrid, Madrid, Spain.
Cardiovascular Centre for Biomedical Research Network (CIBER CV) Health Institute Carlos III, Madrid, Spain.

Arantzazu Alfranca (A)

Immunology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.
Department of Medicine, School of Medicine, Universidad Autónoma of Madrid, Madrid, Spain.
Cardiovascular Centre for Biomedical Research Network (CIBER CV) Health Institute Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH